SOL Stock Analysis: SOL S.p.A. | MI
Specialty Chemicals | MI, Italy | Market Cap: 4.843m EUR | 12M Return: 9.9% | IT0001206769 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.57M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
SOL S.p.A. is an Italy-based producer and distributor of technical and medical gases, serving industrial customers and healthcare facilities both domestically and internationally. Founded in 1927 and headquartered in Monza, the company operates as a subsidiary of Gas And Technologies World B.V. Its industrial portfolio covers a broad range of gases (oxygen, nitrogen, argon, hydrogen, carbon dioxide, helium, acetylene, ammonia, and liquefied natural gas) along with related equipment, systems, and services. Its healthcare division supplies medical gases, electromedical equipment, respiratory and infusion therapies, hospital hygiene and environmental monitoring, ambulance management, biobank design, and digital health solutions. The company also runs specialized units: CRYOLAB for biological sample storage, DIATHEVA for diagnostics and research products such as monoclonal antibodies and molecular kits, and PERSONAL GENOMICS for preventive and precision medicine.
The industrial gases industry is capital-intensive, with players typically relying on long-term supply contracts, on-site generation systems, and a distributed network of production and storage assets to serve customers across manufacturing, healthcare, and food sectors. Medical gases represent a more regulated segment, with demand closely tied to hospital activity and requiring specific certifications and distribution controls.
- Natural gas and energy input costs pressure margins
- Industrial gas volumes track European manufacturing PMI
- Home healthcare and telemedicine services accelerate segment growth
| Net Income: 125.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -0.19 > 1.0 |
| NWC/Revenue: 45.95% < 20% (prev 32.67%; Δ 13.28% < -1%) |
| CFO/TA 0.11 > 3% & CFO 276.8m > Net Income 125.3m |
| Net Debt (609.2m) to EBITDA (361.3m): 1.69 < 3 |
| Current Ratio: 2.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (90.7m) vs 12m ago 0.10% < -2% |
| Gross Margin: 37.81% > 18% (prev 19.37%; Δ 18.43% > 0.5%) |
| Asset Turnover: 57.60% > 50% (prev 75.50%; Δ -17.90% > 0%) |
| Interest Coverage Ratio: 6.49 > 6 (EBIT TTM 191.5m / Interest Expense TTM 29.5m) |
| A: 0.25 (Total Current Assets 1.16b - Total Current Liabilities 522.1m) / Total Assets 2.56b |
| B: 0.04 (Retained Earnings 90.8m / Total Assets 2.56b) |
| C: 0.08 (EBIT TTM 191.5m / Avg Total Assets 2.41b) |
| D: 0.89 (Book Value of Equity 1.18b / Total Liabilities 1.32b) |
| Altman-Z'' = 3.22 = A |
| DSRI: 1.42 (Receivables 620.3m/537.8m, Revenue 1.39b/1.71b) |
| GMI: 0.51 (GM 19.37% / 37.81%) |
| AQI: 1.00 (AQ_t 0.17 / AQ_t-1 0.17) |
| SGI: 0.81 (Revenue 1.39b / 1.71b) |
| TATA: -0.06 (NI 125.3m - CFO 276.8m) / TA 2.56b) |
| Beneish M = -3.26 (Cap -4..+1) = AA |
As of September 27, 2026, the stock is trading at EUR 55.50 with a total of 23,500 shares traded. Over the past week, the price has changed by +1.09%, over one month by +5.51%, over three months by -5.61% and over the past year by +9.87%.
Current recommended Stop Loss: 51.70 (which is 6.8% or 2.2 ATR below the current price).
SOL S.p.A. has no consensus analysts rating.
P/E Trailing = 27.8125
P/E Forward = 1.2114
P/S = 2.5812
P/B = 4.1134
Revenue TTM = 1.39b EUR
EBIT TTM = 191.5m EUR
EBITDA TTM = 361.3m EUR
Long Term Debt = 659.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 3.95m EUR (from shortLongTermDebt, last quarter)
Debt = 895.8m EUR (from shortLongTermDebtTotal, last fiscal year) + Leases 66.9m
Net Debt = 609.2m EUR (calculated: Debt 895.8m - CCE 286.6m)
Enterprise Value = 5.45b EUR (4.84b + Debt 895.8m - CCE 286.6m)
Interest Coverage Ratio = 6.49 (Ebit TTM 191.5m / Interest Expense TTM 29.5m)
EV/FCF = 219.1x (Enterprise Value 5.45b / FCF TTM 24.9m)
FCF Yield = 0.46% (FCF TTM 24.9m / Enterprise Value 5.45b)
FCF Margin = 1.79% (FCF TTM 24.9m / Revenue TTM 1.39b)
Net Margin = 9.01% (Net Income TTM 125.3m / Revenue TTM 1.39b)
Gross Margin = 37.81% ((Revenue TTM 1.39b - Cost of Revenue TTM 864.8m) / Revenue TTM)
Gross Margin QoQ = 77.14% (prev 16.51%)
Tobins Q-Ratio = 2.13 (Enterprise Value 5.45b / Total Assets 2.56b)
Interest Expense / Debt = 3.29% (Interest Expense 29.5m / Debt 895.8m)
Taxrate = 31.04% (19.9m / 64.0m)
NOPAT = 132.0m (EBIT 191.5m * (1 - 31.04%))
Current Ratio = 2.22 (Total Current Assets 1.16b / Total Current Liabilities 522.1m)
Debt / Equity = 0.76 (Debt 895.8m / totalStockholderEquity, last quarter 1.18b)
Debt / EBITDA = 1.69 (Net Debt 609.2m / EBITDA 361.3m)
Debt / FCF = 24.48 (Net Debt 609.2m / FCF TTM 24.9m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.19% (Net Income 125.3m / Total Assets 2.56b)
RoE = 11.37% (Net Income TTM 125.3m / Total Stockholder Equity 1.10b)
RoCE = 10.87% (EBIT 191.5m / Capital Employed (Equity 1.10b + L.T.Debt 659.4m))
RoIC = 6.32% (NOPAT 132.0m / Invested Capital 2.09b)
WACC = 5.76% (E(4.84b)/V(5.74b) * Re(6.40%) + D(895.8m)/V(5.74b) * Rd(3.29%) * (1-Tc(0.31)))
Discount Rate = 6.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -26.74 | Cagr: 0.03%
[DCF] Terminal Value 74.65% ; FCFF base≈25.5m ; Y1≈24.4m ; Y5≈23.5m
[DCF] Fair Price = N/A (negative equity: EV 369.0m - Net Debt 609.2m = -240.2m; debt exceeds intrinsic value)
Revenue Correlation: 5.08 | Revenue CAGR: 0.49% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=2.04 | Chg30d=-1.06% | Revisions=+17% | GrowthEPS=+10.9% | GrowthRev=+9.4%
EPS next Year (2027-12-31): EPS=2.29 | Chg30d=+3.21% | Revisions=+25% | GrowthEPS=+12.0% | GrowthRev=+8.0%
[Analyst] Revisions Ratio: +29% (up=3, down=1)